Disease · HP_0002307
Drooling
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Drooling. Diseases, record HP_0002307. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002307
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Drooling
- Open Targets ID
- HP_0002307
- Other names
- Dribbling, Sialorrhea
- Highest stage of its drugs
- Approval, for 1 of its 14 drugs, from EMA Human Drugs
Source Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| GLYCOPYRRONIUM BROMIDE | CHEMBL1201027 | Small molecule | Approval | EMA Human Drugs | 4 | 3 | 3 | Drugs and targets |
| BOTULINUM TOXIN TYPE A | CHEMBL4297862 | Protein | Phase 3 | ClinicalTrials.gov | 6 | 6 | 3 | Drugs and targets |
| RIMABOTULINUMTOXINB | CHEMBL1201569 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| INCOBOTULINUMTOXINA | CHEMBL2108035 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets | |
| ONABOTULINUMTOXINA | CHEMBL1201574 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets | |
| LETIBOTULINUMTOXINA | CHEMBL3707322 | Phase 3 | ClinicalTrials.gov | 2 | 2 | 0 | Drugs and targets | |
| AMISULPRIDE | CHEMBL243712 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MOCLOBEMIDE | CHEMBL86304 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SCOPOLAMINE | CHEMBL569713 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IPRATROPIUM BROMIDE | CHEMBL2134724 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets38
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | 4 | Muscarinic acetylcholine receptor M3 antagonist | Approval | https://conductscience.org/library/genes/1131 | Drugs and targets |
| SNAP25 | Synaptosomal-associated protein 25 | 4 | Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor | Phase 3 | https://conductscience.org/library/genes/6616 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 2 | Muscarinic acetylcholine receptor M1 antagonist | Approval | https://conductscience.org/library/genes/1128 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/151 | Drugs and targets |
| ADRA2C | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 agonist | Phase 2 | https://conductscience.org/library/genes/152 | Drugs and targets |
| CHRM2 | Muscarinic acetylcholine receptor M2 | 1 | Muscarinic acetylcholine receptor M2 antagonist | Phase 2 | https://conductscience.org/library/genes/1129 | Drugs and targets |
| DRD2 | Dopamine receptors; D2 & D3 | 1 | Dopamine receptors; D2 & D3 antagonist | Phase 3 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| DRD3 | Dopamine receptors; D2 & D3 | 1 | Dopamine receptors; D2 & D3 antagonist | Phase 3 | https://conductscience.org/library/genes/1814 | Drugs and targets |
| HTR1A | Serotonin (5-HT) receptor | 1 | Serotonin (5-HT) receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3350 | Drugs and targets |
1 to 10 of 38
See all 38 targetsTrials21
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02270736 | Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability | Phase 3 | 256 | 2021-01-20 | Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury, Intellectual Disability | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT01994109 | Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Adult Subjects | Phase 3 | 187 | 2019-08-15 | Sialorrhea | RIMABOTULINUMTOXINB | Its record names the disease | ClinicalTrials.gov |
| NCT02610868 | Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults | Phase 3 | 187 | 2019-11-04 | Sialorrhea | RIMABOTULINUMTOXINB | Its record names the disease | ClinicalTrials.gov |
| NCT02091739 | Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions | Phase 3 | 184 | 2018-02-15 | Chronic Troublesome Sialorrhea, Parkinson's Disease, Post-stroke, Traumatic Brain Injury | INCOBOTULINUMTOXINA | Its record names the disease | ClinicalTrials.gov |
| NCT00491894 | Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions | Phase 3 | 137 | 2012-07-09 | Cerebral Palsy, Neurological Conditions, Mental Retardation, Sialorrhea | GLYCOPYRRONIUM BROMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00515437 | A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients | Phase 2 | 54 | 2009-08-13 | Drooling | RIMABOTULINUMTOXINB | Its record names the disease | ClinicalTrials.gov |
| NCT01370811 | A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease | Phase 2 | 24 | 2023-04-10 | Sialorrhoea | CLONIDINE, OXYBUTYNIN | Its record names the disease | ClinicalTrials.gov |
| NCT00761137 | Safety and Efficacy Study of NH004 Films for Relief of Sialorrhea Symptoms in Parkinson's Disease Patients | Phase 2 | 19 | 2015-10-12 | Sialorrhea Secondary to Parkinson's Disease | TROPICAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT06370195 | Effect of Stellate Ganglion Block on Drooling in Parkinson's Syndrome | Not applicable | 100 | Parkinson's Syndrome | LIDOCAINE HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT04873115 | Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties, | Phase 4 | 80 | Sialorrhea, Neurodevelopmental Disorders | GLYCOPYRRONIUM BROMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 21
See all 21 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials11
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002307
GET https://conductscience.org/api/diseases/v1/HP_0002307/targets?page=2